
|Videos|July 22, 2016
Dr. Hristos Kaimakliotis on Predictive Markers in Bladder Cancer
Author(s)Hristos Kaimakliotis, MD
Advertisement
Hristos Kaimakliotis, MD, assistant professor, Indiana University School of Medicine, discusses predictive markers in bladder cancer.
Homologous recombination repair-deficiency (HRD) and cell cycle progression (CCP) have been identified in DNA repair pathways as potential predictors of tumor behaviors, says Kaimakliotis.
After investigating HRD and CCP assays, it was determined that higher CCP and HRD scores were associated with pathological complete responses (pCR) and decreased risk of recurrence.
In a mutation analysis, it was determined that P53 and RB1 mutations were associate with pCRs as well.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5




































